As part of our vision to broaden the choices available for hemophilia treatment, we are excited to be working on several products that we believe will positively impact the lives of people living with hemophilia and related complications. Two of our product candidates are in advanced clinical development:
IB1001 is an intravenous recombinant factor IX (rFIX) product being developed for the treatment and prevention of bleeding in people with hemophilia B. Inspiration has submitted marketing applications for IB1001 in the EU and the US.
Upon licensure, IB1001 is expected to be the second rFIX treatment to market, which will increase treatment choices for people with hemophilia. More information about IB1001 is expected to become available later in 2012.
OBI-1 is a recombinant porcine factor VIII (rpFVIII) being investigated for the treatment of bleeding in people with hemophilia A with inhibitors and acquired hemophilia A.
In November 2010, OBI-1 entered late-stage clinical testing in people with acquired hemophilia A. In August 2011, Inspiration initiated a second late-stage clinical trial in people with congenital hemophilia A who have developed inhibitors to human FVIII.